These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37553165)

  • 1. Tumor biology and impact on timing of surgery in advanced epithelial ovarian cancer.
    Tsibulak I; Fotopoulou C
    Int J Gynecol Cancer; 2023 Oct; 33(10):1627-1632. PubMed ID: 37553165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
    Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
    Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
    Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7).
    Reuss A; du Bois A; Harter P; Fotopoulou C; Sehouli J; Aletti G; Guyon F; Greggi S; Mosgaard BJ; Reinthaller A; Hilpert F; Schade-Brittinger C; Chi DS; Mahner S
    Int J Gynecol Cancer; 2019 Oct; 29(8):1327-1331. PubMed ID: 31420412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy.
    Lyons YA; Reyes HD; McDonald ME; Newtson A; Devor E; Bender DP; Goodheart MJ; Gonzalez Bosquet J
    Int J Gynecol Cancer; 2020 Jun; 30(6):845-852. PubMed ID: 32341114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
    Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
    Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy.
    Maheshwari A; Kumar N; Gupta S; Rekhi B; Shylasree TS; Dusane R; Bajpai J; Ghosh J; Gulia S; Deodhar K; Menon S; Popat P; Sable N; Thakur M; Kerkar R
    Indian J Cancer; 2018; 55(1):50-54. PubMed ID: 30147093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal primary therapy of ovarian cancer.
    Bookman MA
    Ann Oncol; 2016 Apr; 27 Suppl 1():i58-i62. PubMed ID: 27141074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgery for advanced epithelial ovarian cancer.
    Hacker NF; Rao A
    Best Pract Res Clin Obstet Gynaecol; 2017 May; 41():71-87. PubMed ID: 27884789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced Ovarian Cancer: Weighing the Risks and Benefits of Surgery.
    Kumar A; Cliby WA
    Clin Obstet Gynecol; 2020 Mar; 63(1):74-79. PubMed ID: 31725415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CHRONO: randomized trial of the CHROnology of surgery after Neoadjuvant chemotherapy for Ovarian cancer.
    Classe JM; Ferron G; Ouldamer L; Gauthier T; Emambux S; Gladieff L; Dupre PF; Anota A
    Int J Gynecol Cancer; 2022 Aug; 32(8):1071-1075. PubMed ID: 35321888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-operative prediction of residual disease after interval cytoreduction for epithelial ovarian cancer using HE4.
    Lof P; van de Vrie R; Korse CM; van Driel WJ; van Gent MDJM; Karlsen MA; Amant F; Lok CAR
    Int J Gynecol Cancer; 2019 Oct; 29(8):1304-1310. PubMed ID: 31515411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical cytoreduction for recurrent epithelial ovarian cancer.
    Al Rawahi T; Lopes AD; Bristow RE; Bryant A; Elattar A; Chattopadhyay S; Galaal K
    Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD008765. PubMed ID: 23450588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes in ovarian cancer patients receiving three versus more cycles of chemotherapy after neoadjuvant treatment and interval cytoreductive surgery.
    Kim JS; Liang MI; Prendergast EN; Alldredge J; Datta A; Hurteau JA; Kirschner CV; Rodriguez G; Vogel TJ; Brooks RA; Cass I; Cohen JG; Penner KR; Wang CE; Diaz Moore ES
    Int J Gynecol Cancer; 2019 Sep; 29(7):1156-1163. PubMed ID: 31352365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant and post-surgical treatment in high-grade epithelial ovarian cancer.
    Wood GE; Ledermann JA
    Best Pract Res Clin Obstet Gynaecol; 2022 Jan; 78():64-73. PubMed ID: 34607745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept.
    Jiang R; Zhu J; Kim JW; Liu J; Kato K; Kim HS; Zhang Y; Zhang P; Zhu T; Aoki D; Yu A; Chen X; Wang X; Zhu D; Zhang W; Jia H; Shi T; Gao W; Yin S; Feng Y; Xiang L; Okamoto A; Zang R
    J Gynecol Oncol; 2020 Sep; 31(5):e86. PubMed ID: 32808504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in high-grade serous ovarian cancer.
    Cardillo N; Devor E; Calma C; Pedra Nobre S; Gabrilovich S; Bender DP; Goodheart M; Gonzalez-Bosquet J
    Acta Obstet Gynecol Scand; 2022 Oct; 101(10):1085-1092. PubMed ID: 35778930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
    Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
    Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.
    Wright AA; Bohlke K; Armstrong DK; Bookman MA; Cliby WA; Coleman RL; Dizon DS; Kash JJ; Meyer LA; Moore KN; Olawaiye AB; Oldham J; Salani R; Sparacio D; Tew WP; Vergote I; Edelson MI
    Gynecol Oncol; 2016 Oct; 143(1):3-15. PubMed ID: 27650684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients.
    Bouvarel B; Colomban O; Frenel JS; Loaec C; Bourgin C; Berton D; Freyer G; You B; Classe JM
    Int J Gynecol Cancer; 2024 Apr; 34(4):574-580. PubMed ID: 38242546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.